Not applicableStudy completedNCT00351156What this trial is testingStudy to Evaluate Blood Cell Lines From Patients With Gaucher DiseaseWho this might be right forGaucher Disease Amicus Therapeutics 50
Not applicableStudy completedNCT03519646What this trial is testingEliglustat on Gaucher Disease Type IIIBWho this might be right forGaucher Disease, Type III National Taiwan University Hospital 4
Not applicableStudy completedNCT07285369What this trial is testingHigh-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)Who this might be right forGaucher Disease, Type 3 Agyany Pharma LTD 12
Post-approval studies (Phase 4)Study completedNCT00365131What this trial is testingStudy of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.Who this might be right forGaucher Disease Type ICerebroside Lipidosis SyndromeClucocerebrosidase Deficiency Disease+2 more Genzyme, a Sanofi Company 40
Not applicableEnrolling By InvitationNCT06627543What this trial is testingEffect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3Who this might be right forGaucher Disease Type 3 Noha Osman 44
Testing effectiveness (Phase 2)Study completedNCT00911560What this trial is testingBivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaWho this might be right forNeuroblastoma Memorial Sloan Kettering Cancer Center 374
Post-approval studies (Phase 4)Study completedNCT04002830What this trial is testingA Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher DiseaseWho this might be right forGaucher Disease, Type 3 Ari Zimran 14
Early research (Phase 1)Study completedNCT03159117What this trial is testingPfizer PF-06688992 in Patients With Stage III or Stage IV MelanomaWho this might be right forMelanoma Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)UnknownNCT05447494What this trial is testingPhase 1/2 Study of CAN103 in Subjects With Gaucher DiseaseWho this might be right forGaucher Disease, Type 1Gaucher Disease, Type 3 CANbridge (Suzhou) Bio-pharma Co., Ltd. 40
Not applicableStudy completedNCT00244582What this trial is testingConvection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher DiseaseWho this might be right forType 2 Gaucher Disease National Institute of Neurological Disorders and Stroke (NINDS) 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT04411654What this trial is testingPhase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Who this might be right forGaucher Disease, Type 2 Prevail Therapeutics 7
Testing effectiveness (Phase 2)Study completedNCT01141491What this trial is testingTrivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease FreeWho this might be right forSarcoma MabVax Therapeutics, Inc. 136
Not applicableLooking for participantsNCT05619900What this trial is testingRegistry of Patients Diagnosed With Lysosomal Storage DiseasesWho this might be right forMucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis IV A+5 more University of California, San Francisco 250
Not applicableAvailableNCT07675031What this trial is testingManaged Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).Who this might be right forType 3 Gaucher Disease Sanofi
Testing effectiveness (Phase 2)Study completedNCT01685216What this trial is testingEfficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher DiseaseWho this might be right forGaucher Disease, Type 3 Shire 7
Testing effectiveness (Phase 2)Study completedNCT00041535What this trial is testingOGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher DiseaseWho this might be right forGaucher Disease National Institute of Neurological Disorders and Stroke (NINDS) 30
Post-approval studies (Phase 4)Study completedNCT00364858What this trial is testingSafety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher DiseaseWho this might be right forGaucher Disease, Type 1Cerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency Disease+2 more Genzyme, a Sanofi Company 95
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07603050What this trial is testingA Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's DiseaseWho this might be right forGaucher Disease Type 3 Shanghai Vitalgen BioPharma Co., Ltd. 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07715084What this trial is testingStudy to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)Who this might be right forGaucher Disease Type 3 Azafaros B.V. 20
Testing effectiveness (Phase 2)Study completedNCT00358150What this trial is testingThe Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher PatientsWho this might be right forGaucher Disease, Type 1Cerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency Disease+2 more Genzyme, a Sanofi Company 26